Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
8.31
USD
-8.48%
-32.60%
+0.24%
LifeMD, Inc. announced that it has received $10.000001 million in funding from Jason Pharmaceuticals, Inc.
On December 12, 2023, LifeMD, Inc. closed the transaction.
Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating
May. 09
MT
Transcript : LifeMD, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08
Earnings Flash (LFMD) LIFEMD Reports Q1 Revenue $44.1M, vs. Street Est of $42.6M
May. 08
MT
Earnings Flash (LFMD) LIFEMD Posts Q1 EPS $0.01, vs. Street Est of $-0.01
May. 08
MT
LifeMD, Inc. Provides Financial Guidance for the Second Quarter of 2024
May. 08
CI
LifeMD, Inc. Revises Financial Guidance for the Full Year of 2024
May. 08
CI
LifeMD, Inc. Announces A New Strategic Partnership Designed to Revolutionize Weight Management Patient Care
May. 02
CI
LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors
Apr. 29
CI
BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating
Apr. 23
MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating
Mar. 12
MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating
Mar. 12
MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating
Mar. 12
MT
LifeMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 11
CI
Transcript : LifeMD, Inc., Q4 2023 Earnings Call, Mar 11, 2024
Mar. 11
Earnings Flash (LFMD) LIFEMD Reports Q4 Revenue $44.9M, vs. Street Est of $40.5M
Mar. 11
MT
Earnings Flash (LFMD) LIFEMD Posts Q4 EPS $0.15, vs. Street Est of $0.03
Mar. 11
MT
LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024
Mar. 11
CI
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating
Jan. 11
MT
LifeMD Provides 2024 Financial Guidance
Jan. 08
RE
LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024
Jan. 08
CI
WeightWatchers Stock Drops 12% After Eli Lilly Launches DTC Weight-Loss Drug Service
Jan. 04
DJ
Medifast, LifeMD Collaborate to Offer Weight Management Solution; Medifast Scraps Quarterly Dividend
Dec. 13
MT
Transcript : LifeMD, Inc., Medifast, Inc. - Special Call
Dec. 13
Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, Inc
Dec. 13
CI
LifeMD, Inc. announced that it has received $10.000001 million in funding from Jason Pharmaceuticals, Inc.
Dec. 11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
LifeMD, Inc. is a direct-to-patient telehealth company, which provides comprehensive virtual and in-home healthcare. The Company operates through two segments: Telehealth and WorkSimpli. Telehealth segment is engaged in telehealth platform, which integrates a clinician-centric electronic medical record (EMR) system, algorithms for case-load balancing and scheduling, customer relationship management functionality, asynchronous communication, secure synchronous, cloud pharmacy and more. Its technology platform, combined with its 50-state affiliated provider network, enables the management of virtual treatment offerings across various health conditions, including, dermatology, urgent and primary care, chronic care management, dermatology, chronic care management and other. Its WorkSimpli segment offers workplace and document services. This segment offers PDFSimpli an online software as a service platform that allows users to create, edit, convert, sign and share PDF documents.
More about the company
Last Close Price
8.31
USD
Average target price
13
USD
Spread / Average Target
+56.44%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1